Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/Docetaxel and Oxaliplatin-Based Chemoradiation in Borderline Resectable Pancreatic Cancer
NCT00761241Phase 2Completed
- Sponsor
- Benaroya Research Institute
- Start
- Sep 2008
- Primary completion
- Mar 2010
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, docetaxel, oxaliplatin, fluorouracil, interferon alfa in pancreatic adenocarcinoma (PDAC), sponsored by Benaroya Research Institute. Started Sep 2008; status: completed.
02
Drugs
gemcitabinedocetaxeloxaliplatinfluorouracilinterferon alfa
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00761241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00761241.